Recent Quotes
My Watchlist
Indicators
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amneal Pharmaceuticals, Inc. - Class A Common Stock (NY:AMRX)

N/A UNCHANGED
Last Price Updated: 7:00 PM EST, Dec 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amneal Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Amneal Launches Authorized Generic for Xyrem® (sodium oxybate) and Receives FDA Approval for Five Complex Generics in the Second Quarter
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amneal Receives U.S. FDA Complete Response Letter for IPX203
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amneal Releases 2022 Environmental, Social and Governance Report Mapped to the United Nations Sustainable Development Goals
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amneal Receives 505(b)(2) NDA Approval from FDA for PEMRYDI RTU®, a Ready-to-Use Oncology Injectable
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amneal Pharma Q1 Exceeds Consensus View On Strength In Complex Generics Portfolio ↗
 
Via Benzinga
News headline image
Recap: Amneal Pharmaceuticals Q1 Earnings ↗
 
Via Benzinga
News headline image
Amneal to Participate at the 2023 Jefferies Healthcare Conference
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amneal Launches Third Biosimilar with FYLNETRA™ (pegfilgrastim-pbbk) in the United States
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amneal Reports First Quarter 2023 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Earnings Preview: Amneal Pharmaceuticals ↗
 
Via Benzinga
News headline image
Expert Ratings for Amneal Pharmaceuticals ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 5, 2023 ↗
Companies Reporting Before The Bell • CNH Industrial (NYSE:CNHI) is estimated to report quarterly earnings at $0.32 per share on revenue of $5.08 billion. 
Via Benzinga
News headline image
Amneal to Participate at the 22nd Annual Needham Virtual Healthcare Conference
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amneal Reports Certain Preliminary First Quarter 2023 Financial Results and Affirms Full Year 2023 Financial Guidance
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amneal to Report First Quarter 2023 Results on May 5, 2023
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Emergent BioSolutions Soars: Analyst Upgrades Stock With Near 100% Upside After FDA's Positive Move ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
  Tuesday's morning session saw 84 companies set new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
  On Monday, 36 companies set new 52-week lows. 
Via Benzinga
News headline image
Amneal Announces U.S. FDA Filing Acceptance of Abbreviated New Drug Application for Naloxone Hydrochloride Nasal Spray, USP, 4mg
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amneal Reports Fourth Quarter and Full Year 2022 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Amneal to Report Fourth Quarter and Full Year 2022 Results on March 2, 2023
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Intercept Surges To Four-Month High After Staving Off Amneal's Generic For 11 Years ↗
Intercept entered a deal with Amneal, likely lining up a series of new settlements. 
Via Investor's Business Daily
News headline image
Amneal Announces Strategic European Partnership with Orion Corporation
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amneal Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag Approval
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amneal to Participate at Upcoming Investor Conferences
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amneal Launches Second Biosimilar with RELEUKO® (filgrastim-ayow) in the United States
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amneal Announces U.S. FDA Filing Acceptance of New Drug Application for IPX203 for the Treatment of Parkinson’s Disease
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amneal Pharmaceuticals: Q3 Earnings Insights ↗
Amneal Pharmaceuticals (NYSE:AMRX) reported its Q3 earnings results on Friday, November 4, 2022 at 06:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Amneal Reports Third Quarter 2022 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.